Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Dennis W. Raisch, John A. Rafi, Cheng Chen & Charles L. Bennett. (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opinion on Drug Safety 15:8, pages 1003-1011.
Read now
Read now
Eunhye Oak & Nancy L. Bartlett. (2016) A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety 15:6, pages 875-882.
Read now
Read now
Anh Pham & Robert Chen. (2015) Brentuximab vedotin for the treatment of Hodgkin’s lymphoma. Expert Review of Hematology 8:4, pages 403-412.
Read now
Read now
Árpád Illés, Ádám Jóna & Zsófia Miltényi. (2015) Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 451-459.
Read now
Read now
Tanya Siddiqi, Sandra H Thomas & Robert Chen. (2014) Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmacogenomics and Personalized Medicine 7, pages 79-85.
Read now
Read now
Matteo Bassetti, Davide Pecori, Elda Righi, Federica Brillo, Barbara Cadeo, Sergio Venturini, Marianna Chiozzotto & Francesco Zaja. (2013) HSV-1 cutaneous infection in a patient with Hodgkin’s lymphoma treated with brentuximab vedotin. Journal of Chemotherapy 25:6, pages 381-382.
Read now
Read now
Chao-Ming Lai & Sandra Horowitz. (2013) Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. Expert Review of Hematology 6:4, pages 361-373.
Read now
Read now
Martin Berghoff, Anne Schänzer, Gerhard C. Hildebrandt, Benjamin Dassinger, Gothje Klappstein, Manfred Kaps, Elke R. Gizewski, Till Acker & Astrid Grams. (2013) Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine. Leukemia & Lymphoma 54:6, pages 1340-1342.
Read now
Read now
Articles from other publishers (27)
Chunting Zhu, Yi Zhao, Fang Yu, Weijia Huang, Wenjun Wu, Jingsong He, Zhen Cai & Donghua He. (2022) Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report. Frontiers in Immunology 12.
Crossref
Crossref
Alberto Picca & Dimitri Psimaras. 2022. Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy
521
536
.
Rafael San-Juan & Mario Fernández-Ruiz. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
417
430
.
Kester A. Phillips & David Schiff. 2021. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook
593
622
.
Umbreen Hafeez, Sagun Parakh, Hui K. Gan & Andrew M. Scott. (2020) Antibody–Drug Conjugates for Cancer Therapy. Molecules 25:20, pages 4764.
Crossref
Crossref
Ashrit Multani & Dora Y. Ho. (2020) JC Polyomavirus Infection Potentiated by Biologics. Infectious Disease Clinics of North America 34:2, pages 359-388.
Crossref
Crossref
Janet M. Chiang, Andrew R. Lai, Mark Anderson & Robert J. Rushakoff. (2020) Severe Insulin Resistance with Diabetic Ketoacidosis After Brentuximab Treatment. AACE Clinical Case Reports 6:2, pages e98-e100.
Crossref
Crossref
L. Drgona, C. Gudiol, S. Lanini, B. Salzberger, G. Ippolito & M. Mikulska. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clinical Microbiology and Infection 24, pages S83-S94.
Crossref
Crossref
Jun Ho YiSeok Jin KimWon Seog Kim. (2017) Brentuximab vedotin: clinical updates and practical guidance. Blood Research 52:4, pages 243.
Crossref
Crossref
L. Gorza, F. Bourdain, J. Gasnault & B. Lapergue. (2016) Interleukine-7 : une thérapeutique prometteuse de la LEMP dans certaines lymphopénies. Rapport de cas et revue de la littérature. Pratique Neurologique - FMC 7:4, pages 276-282.
Crossref
Crossref
Geetika Bhatt, Kami Maddocks & Beth Christian. (2016) CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Current Hematologic Malignancy Reports 11:6, pages 480-491.
Crossref
Crossref
Chong Hyun Suh, Sree H Tirumani, Abhishek Keraliya, Kyung Won Kim, Nikhil H Ramaiya & Atul B Shinagare. (2016) Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. The British Journal of Radiology 89:1066, pages 20160086.
Crossref
Crossref
Roderick P. P. W. M. Maas, Annemarie H. G. Muller-Hansma, Rianne A. J. Esselink, Jean-Luc Murk, Clemens Warnke, Joep Killestein & Mike P. Wattjes. (2016) Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. Journal of Neurology 263:10, pages 2004-2021.
Crossref
Crossref
Salim Chahin & Joseph R. Berger. (2014) A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. Journal of NeuroVirology 21:6, pages 623-631.
Crossref
Crossref
Rajiv S. Magge & Lisa M. DeAngelis. (2015) The double-edged sword: Neurotoxicity of chemotherapy. Blood Reviews 29:2, pages 93-100.
Crossref
Crossref
Kenneth R. Carson, Scott D. Newsome, Ellen J. Kim, Nina D. Wagner-Johnston, Gloria von Geldern, Craig H. Moskowitz, Alison J. Moskowitz, Alain H. Rook, Pankaj Jalan, Alison W. Loren, Daniel Landsburg, Thomas Coyne, Donald Tsai, Dennis W. Raisch, LeAnn B. Norris, P. Brandon Bookstaver, Oliver Sartor & Charles L. Bennett. (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120:16, pages 2464-2471.
Crossref
Crossref
Nancy L. Bartlett & Kelley V. Foyil. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
2018
2032.e4
.
Maureen M. O’Brien, Michael J. Absalon, Thomas G. Gross & Kara M. Kelly. 2014. Hematopoietic Cell Transplantation in Children with Cancer. Hematopoietic Cell Transplantation in Children with Cancer
251
301
.
Joshua J. Chalkley & Joseph R. Berger. (2013) Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis. Current Neurology and Neuroscience Reports 13:12.
Crossref
Crossref
Guilherme Fleury Perini & Barbara Pro. (2013) Brentuximab Vedotin in CD30+ Lymphomas. Biologics in Therapy 3:1, pages 15-23.
Crossref
Crossref
Jonathan Feld, Stefan K. Barta, Carolina Schinke, Ira Braunschweig, Yiyu Zhou & Amit K. Verma. (2013) Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology. Oncotarget 4:3, pages 397-412.
Crossref
Crossref
Lapo Alinari, Pierluigi Porcu & Bertrand Coiffier. 2013. T-Cell Lymphomas. T-Cell Lymphomas
243
261
.
Amy Grimsley, Katherine S. Shah & Trevor McKibbin. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
337
359
.
. (2012) Brentuximab vedotin. Reactions Weekly 1431:1, pages 12-12.
Crossref
Crossref
R. Angelo de Claro, Karen McGinn, Virginia Kwitkowski, Julie Bullock, Aakanksha Khandelwal, Bahru Habtemariam, Yanli Ouyang, Haleh Saber, Kyung Lee, Kallappa Koti, Mark Rothmann, Marjorie Shapiro, Francisco Borrego, Kathleen Clouse, Xiao Hong Chen, Janice Brown, Lara Akinsanya, Robert Kane, Edvardas Kaminskas, Ann Farrell & Richard Pazdur. (2012) U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma. Clinical Cancer Research 18:21, pages 5845-5849.
Crossref
Crossref
Fariha Zaheer & Joseph R. Berger. (2012) Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Therapeutic Advances in Drug Safety 3:5, pages 227-239.
Crossref
Crossref
Sagun D. Goyal & Nancy L. Bartlett. (2012) Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?. Current Hematologic Malignancy Reports 7:3, pages 179-185.
Crossref
Crossref